The therapeutic utility of recombinant adenoviruses (rAds) is limited in part by difficulties in directing the viruses to specific sites and by the requirement for bolus administration, both of which limit the efficiency of target tissue infection. As a first step toward overcoming these limitations, rAds were encapsulated in coacervate microspheres comprised of gelatin and alginate followed by stabilization with calcium ions. Ultrastructural evaluation showed that the microspheres formed in this manner were 0.8 -10 M in diameter, with viruses evenly distributed. The microspheres achieved a sustained release of adenovirus with a nominal loss of bioactivity. The pattern of release and the total amount of virus released was modified by changes in microsphere formulation. Administration of the adenovirus-containing microspheres to human tumor nodules engrafted in mice showed that the viral transgene was transferred to the tumor cells. It is concluded that coacervate microspheres can be used to encapsulate bioactive rAd and release it in a time-dependent manner.
M ultiple vector systems have been proposed for cancer gene therapy, but arguably the best available is the E1-defective recombinant adenovirus (rAd). Advantages include the extensive understanding of the biology of the virus, the well-established methods for the generation of high-titer rAds, and the generally high expression of the viral transgene, among others (reviewed in Ref. 1) . Important limitations of the existing adenoviral vectors include the inability to achieve the following: (a) targeted delivery of the rAds by systemic administration; (b) extended, local delivery of the adenovirus (Ad) without the requirement for frequent redosing; and (c) transduction of a large fraction of cells comprising tumor masses.
With respect to the latter limitation, researchers at this laboratory have been exploring means of amplifying conventional adenoviral transduction efficiency and transgene expression. We have shown that codelivery of an E1-defective Ad and either plasmid or RNA encoding the deleted E1 functions amplifies adenoviral transgene expression and the "therapeutic effect." [2] [3] [4] In a different approach, we have also shown that the pharmacologic modulation of rAd-infected cells by histone deacetylase inhibitors markedly amplified cytomegalovirus (CMV)-directed transgene expression by a transcriptional mechanism. 5 Both of the strategies described would be enhanced by methods for copackaging both the virus and the amplifying agent into a single "vector." In this context, the first step is the development of a system that packages Ad in a bioactive and releasable form. It was hypothesized here that microspheres might be capable of fulfilling these two important goals. Microspheres might not only offer opportunities for the codelivery of virus and amplifying agents but may also provide a means of achieving extended virus release by modulation of the formulation. In addition, in vivo biodistribution of the microspheres could be modified by changes in size or by the attachment of targeting moieties to the microsphere exterior without requiring any modification of the encapsulated virus. As a first step toward investigating the possible utility of microspheres for addressing the shortcomings of the present Ad vector systems, coacervate microspheres were used to encapsulate rAd in the experiments reported here.
MATERIALS AND METHODS

Microsphere synthesis
Microspheres were created by the coacervation of gelatin and alginate in the presence of rAd. AdCMV-luc (10 8 plaqueforming units (PFU)) 6 was mixed with 1 mL of 0.1% sodium alginate solution. A total of 1 mL of 3.5% gelatin solution was heated to 50°C and added while gently vortexing the alginate-virus mixture. Under these conditions, a phase separation occurred with the formation of microspheres containing entrapped Ad. The microsphere solution was treated with CaCl 2 of varying concentrations as indicated in the text (see Fig 3) for varying amounts of stabilization. The microspheres were then separated from the supernatant by sucrose gradient centrifugation. The microspheres were separated from the sucrose by dialyzing against a 1% mannitol solution for 4 hours and were subsequently frozen, lyophilized, and stored at 4°C.
Physical characterization
Microspheres were rehydrated in a minimal volume of water, air dried, and examined by scanning electron microscopy (SEM) to characterize the external features of the microspheres. The AdCMV-luc virus was labeled by incubation with a fluorescently tagged antibody (Ab) directed against a viral capsid protein. Fluorescein isothiocyanate (FITC)-labeled Ab to the Ad hexon protein was commercially obtained (anti-Ad type 2 hexon, Accurate Chemical and Scientific Corporation, Westbury, NY). Measured amounts of the Ab and the virus were mixed to achieve a 1:1 Ab to rAd stoichiometric ratio and allowed to react at room temperature for 30 minutes. The unbound Ab was removed by dialysis against phosphatebuffered saline overnight. Microspheres were prepared for microscopic examination under conditions similar to those used for the SEM, irradiated by a 488-Å argon laser, and light-sectioned by confocal microscopy.
In vitro release assays
Serial sampling of media incubated with the microspheres was performed to assess the time-dependent release of rAd from the microspheres. By quantifying the virus remaining in the supernatant, it was estimated that 72-75% of the rAd was encapsulated in the microspheres used for these experiments. By quantifying the gelatin remaining in the liquid phase after coacervation, it was estimated that the total mass of the microspheres was 6.5 mg Ϯ 1%, which was subsequently divided into three equal aliquots for the calcium stabilization. One-third of each lot of the microspheres was hydrated in 3 mL of media (Dulbecco's modified Eagle's medium/F12 supplemented with 10% fetal calf serum, 2 mM glutamine, and antibiotics). The microspheres were transferred to microfuge tubes and incubated at 37°C with agitation for the duration of the assay. At each sampling time, as defined in the text (see Fig  3) , the tubes were centrifuged at 300 ϫ g at room temperature to pellet the microspheres and the supernatant was carefully aspirated and replaced with fresh media. Samples were stored at Ϫ70°C. The rAd present in each sample was quantified by plaque assay using our previously described methods. 4 
In vivo release assays
The ability of the microspheres to release rAd was assessed by quantification of the adenoviral transgene expression in human lung cancer xenografts that had received a single injection of the microspheres. Athymic nude mice were engrafted with the H1299 cell lines by a subcutaneous injection (2 ϫ 10 6 cells/ injection) into the flanks using our previously described methods. 3 At the time that tumors were ϳ10 -15 mm in greatest diameter, they were injected with microspheres or free AdCMV-luc by a single intratumoral (i.t.) injection (60 L volume) with a 27-gauge needle. The microspheres were suspended at a concentration of 2 g/L. The free Ad was diluted in media to achieve the required concentrations for delivery of 10 5 or 10 6 PFU. Mice were sacrificed at 3 days postinjection, and the tumor nodules were removed by dissection. Each nodule was weighed and homogenized; the luciferase activity was normalized to the protein concentration, and tumor mass was determined using our previously described techniques.
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RESULTS AND DISCUSSION
The coacervation of gelatin and alginate in the presence of rAd yielded spheres containing the Ad. SEM showed that the coacervate was composed of regular spheres that ranged in diameter from 0.8 to 10 M (Fig 1) . Confocal microscopy of microspheres made with FITClabeled Ad showed that the microspheres contained Ad in a relatively uniform distribution (Fig 2) .
Release assays showed that bioactive virus was released from the coacervate microspheres in a timedependent fashion (Fig 3) . Three lots of microspheres were made with identical amounts of virus, alginate, and gelatin, followed by different calcium cross-linking conditions for stabilization. In these assays, all three lots of spheres released significant amounts of virus at the initial 30-minute sampling point. Those spheres that were stabilized with 3% and 1.5% calcium had similar release curves that showed a sustained release of Ad over the first 3.5 hours, although the majority of the virus was released in the first 1.5 hours. In contrast, the 0.75% stabilized spheres released minimal additional amounts of virus beyond the 30-minute sampling point. Although the pattern of release in the 3.0% and 1.5% spheres was similar, the total amount of virus released varied significantly between these two lots. The 3.0% spheres released a total of 2.4 ϫ 10 6 PFU/mL over the entire assay period compared with the 1.5% lot, which released a total of 15.0 ϫ 10 6 PFU/mL. The 0.75% lot released a total of 4.5 ϫ 10 6 PFU/mL. Based on these results, it seems that the microspheres stabilized with the 1.5% calcium provided a sustained release of the largest amount of virus.
Human lung cancer xenografts displayed luciferase activity after i.t. administration of the microspheres containing the AdCMV-luc (Fig 4) . The non-small-cell lung cancer cell line H1299 was engrafted into the flanks of nude mice to form tumor nodules. Microspheres, or free rAds, were administered by a single i.t. injection of each nodule. The relative gene transfer accomplished by the microspheres or by free rAd was estimated by quantification of the luciferase activity. This analysis showed that the nodules treated with the microspheres had luciferase activities that were significantly greater than those treated with 10 5 PFU of free viruses (P Ͻ .04) and insignificantly different from the nodules treated with 10 6 PFU of free virus (P Ͼ .56). Two lines of evidence shown here demonstrate that bioactive rAd could be encapsulated in, and subsequently released from, coacervate microspheres composed of gelatin and alginate. First, the confocal microscopic characterization of the microspheres made with tagged rAd showed that virus was present in a relatively homogeneous distribution within the spheres. Second, in vitro release studies with the microspheres showed a time-dependent release of virus. It is important to note that the microspheres were subjected to sucrose gradient centrifugation and dialysis before lyophilization to avoid the presence of free rAd in the final, lyophilized preparations. Furthermore, free virus would not explain the sustained release observed in the microsphere formulations tested here.
The results of the in vitro assays suggested that the rAd tolerated these encapsulation conditions with a minimal loss of bioactivity. In the microspheres stabilized with 1.5% calcium, the virus released was 1.5 ϫ 10 7 PFU/mL over 48 hours with a total assay volume of 3 mL, to achieve a total of 4.5 ϫ 10 7 PFU. As explained in Materials and Methods, it was estimated that ϳ2.5 ϫ 10 7 PFU were encapsulated in each aliquot of the spheres tested in the release assays. Based on these estimates, the microspheres released more bioactive virus than was incorporated into the spheres, which most likely reflects the combined degree of error in the estimates of virus incorporation and in the plaque assay quantifications of virus used for both input and output determinations. Despite these limitations of accuracy, these results strongly suggest that the process of microsphere synthesis and lyophilization did not significantly reduce the viral bioactivity. The total amount of virus released was less in the two other microsphere formulations and was most likely the consequence of retained virus, because the calcium concentration was not expected to significantly modify the bioactivity.
The choice of the coacervate microsphere formulation was based in part on the gentle conditions required for microsphere formation before lyophilization. We initially explored microspheres made with alginate chelated with calcium, because those conditions were also favorable for rAd bioactivity (data not shown). However, the chelated alginate microspheres had several unfavorable characteristics. First, they had to be stored in the aqueous phase, either liquid or frozen. In the frozen state, the virus bioactivity was variably affected because it was not in a glycerol-containing buffer. In the liquid state, virus started diffusing from the microspheres immediately after formation, so that the characteristics of each lot of spheres changed continually over time. Second, the formulations required to permit virus release resulted in delicate spheres that did not store or ship well.
We were originally dissuaded from pursuing the coacervate microspheres because of the lyophilization requirement. In preliminary experiments, it was found that lyophilization of free Ad resulted in a major loss of Ad bioactivity. However, it was unexpectedly found that lyophilization of the virus within the microsphere greatly minimized the bioactivity loss. The ability to store the microspheres at 4°C in the lyophilized state was a major advantage in that the characteristics of each lot of spheres changed more slowly over time than was the case with alginate spheres; fragility was no longer a problem.
The importance of the sustained release of a vector at the target site is unclear. Earlier findings by Culver et al, in which administration of retroviral producer cells into a tumor mass resulted in a higher transduction efficiency than did bolus i.t. administration, suggested that sustained vector release was important. 7 Clearly, the superior transduction efficiency with the retroviral producer cells may also have been in part the consequence of the greater virus dose provided by the in situ viral producer cells compared with bolus administration. In the findings presented here, the amount of microspheres administered was estimated to have 1.4 ϫ 10 6 PFU, which resulted in an estimated gene transfer efficiency that was comparable with the tumors treated with 10 6 PFU alone. Although these results did not demonstrate a superior gene transfer efficiency under these conditions, it is possible that differently formulated microspheres or an assessment of later timepoints after transduction may have yielded different results.
We have reported previously that similar coacervate microspheres could be conjugated at the surface with monoclonal Abs that preferentially direct the microspheres to the lung or to the hematopoietic system. 8 It seems reasonable to speculate that similar strategies could be used with the Ad-containing microspheres as a means of modifying biodistribution in vivo. 5 free AdCMV-luc (free 1eϩ05), or 10 6 free AdCMV-luc (free 1eϩ06) is shown. For microspheres, n ϭ 12; for the other two groups, n ϭ 6 for each. Luciferase activity is shown on the ordinate as relative light units (RLU) normalized to the protein content of the lysate Ϯ SEM.
